Evidence map›Paper›PMID 24169850›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2014

Transplantation of cryopreserved human umbilical cord blood mononuclear cells does not induce sustained recovery after experimental stroke in spontaneously hypertensive rats.

Gesa Weise, Marlene Lorenz, Claudia Pösel, Ute Maria Riegelsberger, Veronika Störbeck, Manja Kamprad, Alexander Kranz, Daniel-Christoph Wagner, Johannes Boltze

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Mesenchymal Stem Cells and Psoriasis: Systematic Review.International journal of molecular sciences · 2022
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gesa Weise1] Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany [2] Translational Center for Regenerative Medicine, University of Leipzig, Leipzig, Germany.
Marlene LorenzFraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Claudia PöselFraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Ute Maria RiegelsbergerFraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Veronika StörbeckFraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Manja Kamprad1] Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany [2] Institute for Clinical Immunology, University of Leipzig, Leipzig, Germany.
Alexander KranzFraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Daniel-Christoph Wagner1] Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany [2] Translational Center for Regenerative Medicine, University of Leipzig, Leipzig, Germany.
Johannes Boltze1] Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany [2] Translational Center for Regenerative Medicine, University of Leipzig, Leipzig, Germany [3] Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have highlighted the enormous potential of cell-based therapies for stroke not only to prevent ischemic brain damage, but also to amplify endogenous repair processes. Considering its widespread availability and low immunogenicity human umbilical cord blood (HUCB) is a particularly attractive stem cell source. Our goal was to investigate the neurorestorative potential of cryopreserved HUCB mononuclear cells (MNC) after permanent middle cerebral artery occlusion (MCAO) in spontaneously hypertensive rats (SHR). Human umbilical cord blood MNC or vehicle solution was administered intravenously 24 hours after MCAO. Experimental groups were as follows: (1) quantitative polymerase chain reaction (PCR) of host-derived growth factors up to 48 hours after stroke; (2) immunohistochemical analysis of astroglial scarring; (3) magnetic resonance imaging (MRI) and weekly behavioral tests for 2 months after stroke. Long-term functional outcome and lesion development on MRI were not beneficially influenced by HUCB MNC therapy. Furthermore, HUCB MNC treatment did not change local growth factor levels and glial scarring extent. In summary, we could not demonstrate neurorestorative properties of HUCB MNC after stroke in SHR. Our results advise caution regarding a prompt translation of cord blood therapy into clinical stroke trials as long as deepened knowledge about its precise modes of action is missing.

Indexed as

AnimalsBrainCryopreservationDisease Models, AnimalFetal BloodHumansLeukocytes, MononuclearMagnetic Resonance ImagingRatsRats, Inbred SHRRecovery of FunctionStrokeTreatment Outcome

Identifiers

PMID24169850
PMCPMC3887359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.